मैट्रिक्स
 
 
पैराबोलिक ड्रग > कंपनी इतिहास > Pharmaceuticals > कंपनी इतिहास का पैराबोलिक ड्रग - बीएसई: 533211, NSE: PARABDRUGS

पैराबोलिक ड्रग

बीएसई: 533211  |  NSE: PARABDRUGS  |  ISIN: INE618H01016  |  Pharmaceuticals

कंपनी इतिहास - पैराबोलिक ड्रग
Our Company was incorporated on February 22, 1996 under the Companies
 Act with the name Parabolic Drugs Limited. We received our
 certificate of commencement of business on March 15, 1996, from the
 RoC.
 
 Key Events and Milestones
 
 Fiscal                            Key events, milestones and
 achievements
 
 1996               Incorporated and received certificate for
 commencement of business
 
 1998                Commencement of commercial production of oral
 Semi Synthetic Penicillin APIs at Derabassi
 
 1999                Initiated contract manufacturing services
 
 2003               Entered into export market through direct and
 third party exports.
 
 2004                Set up of our regulatory affairs department for
 the filings of our dossiers
 
 2005
                        Commenced commercial production from Unit II
 at Panchkula and capacity enhanced by 360 TPA
 
                         2 dossiers filed in the European Union for
 CoS
 
                         Launch of our first Cephalosporin oral API
 (Cefixime Trihydrate)
 
                         Our Company was awarded WHO-GMP certificate
 for Amoxicillin Trihydrate and Flucloxacillin
                         Sodium vide certificate no.09 & 10 dated
 October 11, 2004
 
 2006                 Commercial operation of new Cephalosporin API
 plant for Cefuroxime Axetil
 
                          USFDA approval for supply of 6-APA to US
 markets
 
 2007                 Raised funding from Alden (formerly Minivet
 Limited) and Exquisite
 
                          Commercial operation of a new plant for
 manufacturing Sterile Semi Synthetic Penicillin API
 
                          Diversification into third and fourth
 generation Cephalosporin API
 
                           Commercial operation of new Cefuroxime
 Axetil (Amorphous) plant
 
 
 2008                  CoS received from the EDQM for Amoxycillin and
 Flucloxacillin allowing exports to the
                          European Union
 
                          3 dossiers filed in US and European Union
 
                           Commercial operation of new multipurpose
 block I for Cephalosporins API
 
                           3 process patents filed with the Indian
 Patent Office
 
 2009                  8 dossiers filed in US, Canada and European
 Union
 
                           Raised funding from BTS
 
                            Commercial operation of new Cefuroxime
 Axetil plant with 100 TPA capacity
 
                            Launch of Sterile Cephalosporin APIs
 
                            4 process patents filed with the Indian
 Patent Office and one PCT application filed
 
 2010                    Commissioning of R&D center at Barwala
 
                             Received an ISO 14001:2004 Management
 System Certificate from Det Norske Veritas
 
                            Diversified into custom synthesis for
 innovator companies under CRAMS model
 
 2011
 
 - Parabolic Drugs receives Certificate of Suitability for Cefixime
 molecule.
 
 - Parabo.Drugs - Parabolic Drugs adds 15% capacity to its
 Cephalosporin facility.
 
 - Pharma firm Parabolic Drugs said that its manufacturing site at
 Derabassi in Punjab has got the accreditation of the Japanese
 Ministry of Health, Labor and Welfare, which will enable the facility
 to supply Cephalosporin non sterile drugs to the Japanese market.
 
 
 2012
 
 - Parabo.Drugs - Commissioning of Sterile Cephalosporin Plant at
 Derabassi.
 
 2013
 
 - Mr. Balwan Bansal has been appointed as an Additional Director on
 the Board of Directors of the Company.
 
 - The Company has changed its Corporate Office Address.
 
 - Approved the appointment of Mr. Balbir singh Bhasin (a nominee of
 State Bank of India) on the Board of the Company.
 
 2014
 
 - Parabolic Drugs Ltd has received European GMP Certifications for
 its:- Works Site located at Derabassi for manufacture of
 Cephalosporin products. (Certificate No. DE_RP_01_GMP_2014_0023) and
 - Works Site located at Lalru for manufacture of Non-beta Lactams
 products. (Certificate No. DE_RP_01_GMP_2014_0024).
 - Mr. Jagjit Singh Chahal has been appointed as a Director on the
 Board of Directors of the Company.
 - Appointed Mrs. Vandana Singla, as an Independent Director of the
 Company.
 
 
स्रोत: रेलीगरे टेचनोवा

न्यूज़ फ़्लैश

  • MARKET CUES : FIIs ने कैश में `1116.79 Cr की बिकवाली की
  • MARKET CUES : DIIs ने कैश में `450.36 Cr की बिकवाली की
  • MARKET CUES : FIIs ने F&O में `58.91 Cr की खरीदारी की
  • MARKET CUES : इंडेक्स फ्यूचर्स में `1197.47 Cr की बिकवाली
  • MARKET CUES : इंडेक्स ऑप्शंस में `1280 Cr की खरीदारी
  • MARKET CUES : स्टॉक फ्यूचर्स में `22.75 Cr की बिकवाली
  • MARKET CUES : स्टॉक ऑप्शंस में `1.60 Cr की बिकवाली
  • CS ON AUROBINDO PHARMA : रेटिंग Neutral से घटाकर Underperform
  • CS ON AUROBINDO PHARMA : लक्ष्य `450/Sh से घटाकर `345/Sh
  • HSBC ON BAJAJ FIN : BUY रेटिंग, लक्ष्य `4,860 से घटाकर `3,750/Sh

अभी देखें

OUR WINNING PICKS

DID YOU INVEST?

INTRADAY PICKS!

(August 06, 2018)

AT (Rs)



GAIN (Rs)

ALL TIME WINNERS

RECO PRICE

PEAK PRICE

OUR PACKAGES

Super Combo

Powerful mix of both trader and investor packs with timely expert advice.

Technical

Designed especially for traders looking to tap the profit opportunities of volatile markets.

Fundamental

For all investors looking to unearth stocks that are poised to move.